Clinical Trial Update: FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study [NA]

View source ↗

Summary

A completed clinical trial evaluating the FLExAbility sensor-enabled substrate-targeted ablation for reduction of ventricular tachycardia, sponsored by Abbott M…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventricular Tachycardia

Snippet

Sponsor: Abbott Medical Devices | Conditions: Ventricular Tachycardia | NA | Status: COMPLETED